Correspondence 0001213900-23-090253 from Allarity Therapeutics, Inc. (ALLR)

Allarity Therapeutics, Inc.
Date: Nov. 27, 2023 · CIK: 0001860657 · Accession: 0001213900-23-090253

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-275282

Date

November 29, 2023

Author

Chief Executive

Form

CORRESP

Company

Allarity Therapeutics, Inc.

Letter

School Street, 2nd Floor

Boston, MA 02108

November 27, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Attention: Jason Drory

Re: Allarity Therapeutics, Inc.

Registration Statement on Form S-3 (File No. 333-275282)

Request for Acceleration

Requested Date: November 29, 2023

Requested Time: 5:00 p.m. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests that the effective date of its Registration Statement on Form S-3 (File No. 333-275282) be accelerated so that the same will become effective at 5:00 p.m., Eastern Time, on November 29, 2023, or as soon thereafter as is practicable.

If you have any questions regarding this request, please contact our counsel Daniel B. Eng of Lewis Brisbois Bisgaard & Smith LLP at (415) 262-8508.

Very Truly Yours,
Allarity Therapeutics, Inc.

Show Raw Text

CORRESP
1
filename1.htm

24
School Street, 2nd Floor

Boston,
MA 02108

November
27, 2023

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
Jason Drory

    Re:
    Allarity Therapeutics, Inc.

    Registration Statement on Form S-3 (File No. 333-275282)

    Request for Acceleration

    Requested Date: November 29, 2023

    Requested Time: 5:00 p.m. Eastern Time

Ladies
and Gentlemen:

In
accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests that the effective
date of its Registration Statement on Form S-3 (File No. 333-275282) be accelerated so that the same will become effective at 5:00 p.m.,
Eastern Time, on November 29, 2023, or as soon thereafter as is practicable.

If
you have any questions regarding this request, please contact our counsel Daniel B. Eng of Lewis Brisbois Bisgaard & Smith LLP at
(415) 262-8508.

    Very Truly Yours,

    Allarity Therapeutics, Inc.

    By:
    /s/
James G. Cullem

    Name:
    James G. Cullem

    Title:
    Chief Executive
    Officer

SecProbe.io